Information

Home Information
  • Dec 19, 2024

Analysis-US stocks face headwind from rising yields after Fed signals fewer rate cuts

NEW YORK (Reuters) -The rally in U.S. stocks is encountering a fresh hurdle -- a potentially problematic rise in Treasury yields as the Federal Reserve signals fewer interest rate cuts for 2025. The central bank's rate outlook on Wednesday included only two cuts in the coming year, rather than the four previously penciled in, catching investors off guard, and sending stocks tumbling while driving up yields and the dollar. That overshadowed the Fed's widely expected decision to reduce its benchmark rate for a third straight meeting.

  • Dec 19, 2024

The Ultimate Guide to Investing in Bitcoin for Maximum Returns

Bitcoin (CRYPTO: BTC) continues to prove that it's one of the best financial assets to own. Any investor, whether the focus is on stocks or cryptocurrencies, certainly understands the concept of buying low and selling high. Bitcoin has had many declines of more than 50%.

  • Dec 19, 2024

Can Dogecoin Reach $1?

Dogecoin (CRYPTO: DOGE) is making a monster comeback. Continue reading to understand Dogecoin's potential price trajectory. This trend provides a clear example of the most obvious bullish case for Dogecoin, which is known as the greater fool theory.

  • Dec 19, 2024

Is the Cryptocurrency XRP a Millionaire Maker?

Several other cryptocurrencies have done well and grown to market caps exceeding $100 billion. One is XRP (CRYPTO: XRP), which currently has the fourth-largest market cap in the crypto sector at more than $140 billion. If you invested in XRP a decade ago, there is a chance you're a millionaire today.

  • Dec 19, 2024

Will Broadcom Stock Have Its 'Nvidia Moment' in 2025?

Some on Wall Street see artificial intelligence-driven demand poised to push sales of Broadcom's chips to fresh highs, powering its stock higher in 2025. But others are more cautious—in the near term, at least.

  • Dec 18, 2024

European Health Stocks Brace for Year Clouded by US Politics

(Bloomberg) -- After falling off their perch in the last few months of 2024, European healthcare stocks head into a new year facing the jeopardy of US politics and high-stakes trial results for new drugs.Most Read from BloombergNYPD Car Chases Are Becoming More Frequent — and More DangerousDakar’s Air Quality Plummets as Saharan Dust Descends on SenegalKey for investors will be clarity on American healthcare policy after president-elect Donald Trump’s nomination of health officials, including a

Popular Post